Back

What is the optimal timing for ventricular tachycardia ablation? ablation should be performed only after failure of anti-arrhythmic drugs

12 April 2026 (17:25 - 17:35)
Organised by: Logo
Congress Presentation Part of: Unanswered questions in post-MI ventricular tachycardia ablation Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Professor Rakesh Gopinathannair

Kansas City Heart Rhythm Institute, Overland Park (United States of America)

5 More presentations in this session

Presentation thumbnail
What is the optimal timing for ventricular tachycardia ablation? ablation should be first-choice treatment after the first implantable cardioverter-defibrillator shock
Doctor J. Sapp (Halifax, CA)
Slides Video
Presentation thumbnail
What is the optimal timing for ventricular tachycardia ablation? discussion
Video
Presentation thumbnail
What is the best strategy for ventricular tachycardia substrate identification? static depiction of the substrate in sinus rhythm is the optimal approach
Doctor C. Bisceglia (Milan, IT)
Slides Video
Presentation thumbnail
What is the best strategy for ventricular tachycardia substrate identification? the dynamic and functional assessment is the key to unlock the true VT substrate
Doctor M. De Riva Silva (Leiden, NL)
Slides Video
Presentation thumbnail
What is the best strategy for ventricular tachycardia substrate identification? discussion
Video

Access the full session

Session thumbnail
Unanswered questions in post-MI ventricular tachycardia ablation
Video

The Event

Event poster

EHRA 2026

12 April 2026 17:25 CET
You may be interested in
thumbnail
Congress Presentation
What is the optimal timing for ventricular tachycardia ablation? ablation should be first-choice treatment after the first implantable cardioverter-defibrillator shock
thumbnail
Congress Presentation
What is the optimal timing for ventricular tachycardia ablation? discussion
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources